Zydus receives tentative approval from the USFDA for Sitagliptin Tablets

Zydus receives tentative approval from the USFDA for Sitagliptin Tablets ________________________________________________________________ Ahmedabad, 11 September, 2018 Zydus Cadila has received the tentative approval from the USFDA for Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg (US RLD –Januvia ® Tablets). It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. Sitagliptin is used along with diet and exer cise and sometimes with other medications to lower blood sugar levels in patients with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Sitagliptin is in a class of medications called d ipeptidyl peptidase -4 (DPP -4) inhibitors. It works by increasing the amounts of certain natural substances that lower blood sugar when it is high. The group now has 217 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedic ated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗